English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Copyright © 2016, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved. • E. coli was the most common Gram-negative isolate from bloodstream infections (n = 6331; 48.5%); K. pneumoniae (n = 2427; 18.6%) and P. aeruginosa (n = 1475; 11.3%) were the second and third most common (Figure 1 and Table 1) • Ceftolozane/tazobactam inhibited 90.6% of all P. aeruginosa and 93.3% of all Enterobacteriaceae bloodstream infection isolates (CLSI breakpoints) (Table 1) – P. aeruginosa susceptibility to ceftolozane/ tazobactam was 96.3% in North America, 86.0% in Europe, and 96.0% in Asia-Western Pacific – Enterobacteriaceae susceptibility to ceftolozane/ tazobactam was 95.2% in North America, 91.4% in Europe, and 99.2% in Asia-Western Pacific • Ceftolozane/tazobactam susceptibility ranged from 80.6% (skin and skin structure [SSS]) to 94.0% (UT) against P. aeruginosa bloodstream infection isolates derived from various identified infection sites – Ceftolozane/tazobactam activity was markedly superior to that of meropenem overall (90.6% vs 75.8% susceptibility for all P. aeruginosa isolates) and against each of the isolate subsets • Ceftolozane/tazobactam was also very active against Enterobacteriaceae bloodstream isolates derived from various sites of infection (% susceptible range, 84.6% lower respiratory tract [LRT] to 95.7% UT) – The only 2 primary infection sites for which Enterobacteriaceae isolates exhibited susceptibility <90% were intravenous line (88.5% susceptible) and LRT (84.6% susceptible), and these constituted only 9.8% of all Enterobacteriaceae isolates • Table 2 shows the 50% minimum inhibitory concentration (MIC50), 90% minimum inhibitory concentration (MIC90), and susceptibility rates (CLSI 2016 breakpoints) for ceftolozane/tazobactam and comparators against P. aeruginosa and Enterobacteriaceae – For P. aeruginosa, ceftolozane/tazobactam and meropenem have the lowest MIC50 (0.5 μg/mL). Ceftolozane/tazobactam also has the lowest MIC90 (4 μg/mL) and the highest percentage susceptible (90.6%) – For Enterobacteriaceae, ceftolozane/tazobactam has a lower MIC90 (1 μg/mL) than all comparators except meropenem (≤0.06 μg/mL) Table 2. Activity of ceftolozane/tazobactam and comparator antimicrobial agents when tested against 1475 isolates of Pseudomonas aeruginosa and 11,588 isolates of Enterobacteriaceae from bloodstream infections (PACTS, 2011-2015)

Ceftolozane/Tazobactam Activity Tested Against Bacterial Bloodstream Isolates From Multiple Infection Sources